A Phase 1 interventional study of yimitasvir and placebo in Chronic Hepatitis c, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-12.
Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hepatitis C, Chronic with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Hepatitis C, Chronic · China.
Among the 44 studies in Hepatitis C, Chronic with a site in China, this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2014, is one of 7 in phase 1, and was the 26th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →2 of the 44 studies in Hepatitis C, Chronic with a site in China are open now. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18–75
The Third Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 20–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 9 · Phase 3 16 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 120 across the 34 interventional studies, 300 across the 10 observational. Of the 32 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 44 have an industry lead sponsor. The 10 most frequent:
Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Sunshine Lake Pharma Co., Ltd. has 7 studies filed under Hepatitis C, Chronic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Hepatitis C, Chronic with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Safety, Tolerability and Pharmacokinetic Study of Chronic Hepatitis C Treatment Drug Yimitasvir in Healthy Adults Subjects.
This was a Randomized,Double-blind, Placebo-controlled, Single Ascending Dose, Single-center Study to Assess the Safety, Tolerability and Pharmacokinetic of Yimitasvir in Healthy Adults Subjects
A total of 56 healthy subjects were divided into 7 groups, with each group consisting of 8 subjects. Six of the subjects received the investigational drug, and two received placebo. All of the subjects received a single dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)
Drug: yimitasvir · Drug: placebo
Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)
Drug: yimitasvir · Drug: placebo
Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)
Drug: yimitasvir · Drug: placebo
Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)
Drug: yimitasvir · Drug: placebo
Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)
Drug: yimitasvir · Drug: placebo
Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)
Drug: yimitasvir · Drug: placebo
Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)
Drug: yimitasvir · Drug: placebo
Capsule administered orally once daily
Also known as: DAG181
Matching Placebo Capsule
Also known as: DAG181 placebo
Adverse events
To assess the safety and tolerability after a single dose of DAG181
Time frame: Baseline to day 10
Cmax
Maximum observed plasma concentration of DAG181
Time frame: Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing
Tmax
Time of the maximum observed plasma concentration
Time frame: Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing
AUC
Area under the plasma concentration-time curve (AUC)
Time frame: Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing
T1/2
Terminal elimination half-life
Time frame: Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2014 to primary completion in Jan 2015, 1 month.
Of 21 phase 1 interventional studies under Hepatitis C, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Yimitasvir
Sunshine Lake Pharma Co., Ltd. →